Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Блубёрд Био, Инк.filedCriticalБлубёрд Био, Инк.
Priority claimed from PCT/US2017/059989external-prioritypatent/WO2018085690A1/en
Publication of EA201991100A1publicationCriticalpatent/EA201991100A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
Настоящее изобретение относится к улучшенным композициям T-клеток с CAR к BCMA для адаптивной T-клеточной терапии рецидивирующей/рефрактерной множественной миеломы.The present invention relates to improved T-cell compositions with CAR for BCMA for adaptive T-cell therapy of recurrent / refractory multiple myeloma.
EA201991100A2017-06-022017-11-03
TMA CELL COMPOSITION WITH CHIMERA ANTIGENIC RECEPTOR FOR BCMA (OPTIONS)
EA201991100A1
(en)